Today: 7 February 2026
Subscribe
Browse Category

NYSE:ELF News 7 December 2025

ELF Stock on December 7, 2025: Why e.l.f. Beauty Crashed, What Wall Street Expects Next, and the 2026 Outlook

ELF Stock on December 7, 2025: Why e.l.f. Beauty Crashed, What Wall Street Expects Next, and the 2026 Outlook

Published: December 7, 2025 Key takeaways This article summarizes the latest news, forecasts and analyses on ELF stock as of December 7, 2025. Where ELF stock stands today e.l.f. Beauty, Inc. (NYSE: ELF) closed recently around $81–82 per share, with an intraday range of roughly $80.03 to $84.38 and a market capitalization near $4.9 billion. Over the last 52 weeks, the stock has traded between $49.40 and $150.99, highlighting how violent the recent drawdown has been. StockAnalysis According to Zacks and related coverage, shares are down roughly 36–39% year to date, significantly underperforming both the S&P 500 and the broader
7 December 2025
·

Stock Market Today

MARA stock jumps 22% into weekend as bitcoin whipsaws; Monday risk test looms

MARA stock jumps 22% into weekend as bitcoin whipsaws; Monday risk test looms

7 February 2026
MARA shares jumped 22.4% to $8.24 Friday, trading higher after hours, as the company moved $87 million in bitcoin to major custodians. About 82.4 million MARA shares changed hands. Bitcoin hovered near $68,928 Saturday. A MARA filing showed its general counsel had shares withheld for taxes on vested stock units, not an open market sale.
Apple stock (AAPL) set for Monday test as memory-chip crunch revives iPhone price question

Apple stock (AAPL) set for Monday test as memory-chip crunch revives iPhone price question

7 February 2026
Apple shares closed up 0.8% at $278.12 Friday, then slipped 0.3% after hours. A global DRAM shortage is raising component costs, putting pressure on Apple’s pricing ahead of its Feb. 24 shareholder meeting. CEO Tim Cook said memory prices will rise “sharply” but gave no details on possible iPhone price hikes. Investors await signals before next week’s U.S. inflation data.
Roivant stock surges on brepocitinib skin-disease data; what to watch into Monday

Roivant stock surges on brepocitinib skin-disease data; what to watch into Monday

7 February 2026
Roivant shares surged 22.4% to $25.82 after Phase 2 data showed its drug brepocitinib outperformed placebo in cutaneous sarcoidosis, with no serious adverse events. The company plans a Phase 3 trial in 2026 and has filed for FDA approval in dermatomyositis. Quarterly revenue reached $2 million, with a $313.7 million loss. Cash holdings stood at $4.5 billion.
Go toTop